Related Experiment Videos
[Calcium antagonists in the treatment of congestive heart failure]
A Pereirinha1, M J Amaro, M G Lopes
1UCIM/Med IV-A, Hospital de Santa Maria, Lisboa.
Insights
Calcium antagonists are not universally effective for chronic heart failure. Their use requires careful patient selection, as they can be detrimental in specific conditions like left ventricular systolic dysfunction but may benefit others with increased afterload.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) is a complex condition with diverse etiologies.
- Calcium antagonists represent a class of drugs with varied effects in cardiovascular disease.
Purpose of the Study:
- To review clinical studies on calcium antagonist use in chronic heart failure.
- To identify patient subgroups that may benefit or experience adverse effects from calcium antagonists.
Main Methods:
- Systematic review of existing clinical studies.
- Analysis of patient characteristics and treatment outcomes associated with calcium antagonist therapy.
Main Results:
- Calcium antagonists may be ineffective or harmful in CHF patients with left ventricular systolic dysfunction, high renin, high right atrial pressure, or low sodium.
- Benefits may be observed in patients with increased afterload or valvular regurgitation, necessitating cautious administration.
- Novel calcium antagonists with reduced adrenergic stimulation and negative inotropic effects show potential.
Conclusions:
- CHF therapy requires individualized approaches due to its multifactorial nature.
- Calcium antagonists can be a component of tailored therapy for specific CHF patient profiles.
- Further research into newer calcium antagonists is warranted for CHF management.
Abstract:
The authors present a revision of the clinical studies using calcium antagonists to treat chronic heart failure. They analyse cases where calcium antagonists seem to be of no use (and can even have an adverse effect), particularly in patients with significant left ventricular systolic dysfunction, with normal afterload, high levels of renin, very high levels of right atrium pressure or low sodium. On the opposite, patients with increased afterload or valvular regurgitation can receive some benefit, although care must be taken in the administration of this kind of drugs. New calcium antagonists may show more benefit because they seem not to stimulate the adrenergic system and do not have significant negative inotropic effects. They conclude with a reference to the multiple situations that can be the basis for heart failure, suggesting that probably, in the future, therapy shall be more individually tailored and that in some cases calcium antagonists can be included in such therapy.